A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 807 participants.

Also called NCT01126580

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 807 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01126580
  • CTRI CTRI/2010/091/003036
Other papers using this trial's data
  • Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3) Diabetes care, 2014-08 DOI, PubMed 24842985

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Brazil, Canada, Croatia, Czechia, Finland, France, Germany, India, Mexico, Poland, Puerto Rico, Romania, Slovakia, South Africa, South Korea, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01126580. Randomized; quadruple masking; primary purpose treatment. Start 2010-05 (registry gives no type); primary completion 2011-11 (actual). Results posted on 2015-01-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Metformin
Intervention (Drug)
LY2189265
Intervention (Drug)
Placebo (oral)
Intervention (Drug)
Placebo (subcutaneous)
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01126580
Content hash
65d1806a8ede96d5d2ff443e285e3dce3ec6268801f682fce9f179f815f9ea2e